Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN PHOSPHATE vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure)
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive)
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic